Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond

Executive Summary

Celgene believes it's acquiring a $1bn drug, not a me-too JAK inhibitor in its purchase of Impact Biomedicines for $1.1bn up front. Investors appeared skeptical of fedratinib's potential, but the company said at the J.P. Morgan meeting that it will execute more deals to build out its pipeline.

Advertisement

Related Content

Keeping Track: Accelerated Approval For Tecentriq And A Burst Of Filings And Submissions
Celgene Gives Reassurances That Key Products And Programs Remain On Track
Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?
Celgene's Focus On Execution Pays Off, But Follow-Through Is Key
Celgene Maintains Otezla Confidence, But Is Reconsidering IBD Indications
Start-Up Quarterly Statistics: Financings Finally Rise In Q1, But Deals Stagnate
Tax Reform Provides Environment For M&A Surge, EY Report Says
Celgene's Partnered Pipeline Delivers Successes And Setbacks
Celgene Admits It Screwed Up Otezla Estimates; Investors Lose Confidence
Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial Ends

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100168

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel